Last reviewed · How we verify
COLD-fX
At a glance
| Generic name | COLD-fX |
|---|---|
| Also known as | CVT-E002 |
| Sponsor | Afexa Life Sciences Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- American Ginseng Extract in Preventing Respiratory Infection and in Reducing Antibiotic Use in Patients With CLL (PHASE2)
- A Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of CVT-E002 in the Treatment of Upper Respiratory Tract Infections in a Pediatric (3-11 Years) Population (PHASE2)
- Use of COLD-fX to Prevent Respiratory Infections in Community Dwelling Seniors (PHASE3)
- A Randomized, Double-blind, Placebo-controlled Study on the Effect of CVT-E002 in Patients With Seasonal Allergic Rhinitis (PHASE2)
- Efficacy of Cold-FX (CVT-E002) in the Prevention of Upper Respiratory Tract Infections in Healthy Adults (PHASE3)
- Safety and Immune Enhancing Effects of Acute Dosing of COLD-fX in Healthy Adults (PHASE2)
- Pilot Evaluation of CVT-E002 in Pediatric Upper Respiratory Tract Infection. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- COLD-fX CI brief — competitive landscape report
- COLD-fX updates RSS · CI watch RSS
- Afexa Life Sciences Inc portfolio CI